Can I Take Quercetin with Wegovy?

What Is Quercetin and Why Do Wegovy Patients Take It?

Quercetin is one of the most abundant dietary flavonoids, found naturally in onions, apples, and capers. Sold as a standalone supplement and in combination products (often paired with bromelain), quercetin is marketed for anti-inflammatory, antihistamine, and antioxidant effects. Many people starting Wegovy add it hoping to blunt the low-grade systemic inflammation associated with obesity or to manage seasonal allergies without adding a separate pharmaceutical antihistamine.

Who Takes Quercetin

Patients on Wegovy frequently carry a long list of comorbidities, including type 2 diabetes, hypertension, and non-alcoholic fatty liver disease. A 2021 analysis published in Nutrients found that flavonoid supplement use was reported by roughly 17% of adults with obesity in the United States, making quercetin one of the more common over-the-counter additions clinicians encounter in this population. [1]

Available Forms and Typical Doses

Standard OTC quercetin products deliver 250 to 1,000 mg per capsule. Quercetin phytosome (bound to sunflower phospholipids) claims higher bioavailability than standard quercetin aglycone. The European Food Safety Authority reviewed quercetin safety in 2011 and set a no-observed-adverse-effect level of 1,000 mg per day in humans based on available data at that time. [2]

How Semaglutide 2.4 mg Is Metabolized

Understanding whether a drug-supplement interaction is possible starts with the drug's metabolic pathway. Semaglutide does not rely on CYP450 enzymes for its clearance.

Semaglutide Pharmacokinetics

Semaglutide is a fatty-acid-modified GLP-1 analogue with a half-life of approximately 7 days. According to the FDA prescribing information for Wegovy, semaglutide is metabolized via proteolytic cleavage and beta-oxidation of the fatty-acid side chain, not via hepatic CYP450 enzymes. [3] The drug is not a substrate of CYP3A4, CYP2C9, or P-glycoprotein.

This means that a supplement inhibiting CYP3A4 (which quercetin does at high concentrations) would not meaningfully change semaglutide blood levels through that pathway.

Gastric Emptying as a Confounding Variable

Semaglutide slows gastric emptying, most prominently during the first four weeks of treatment. [3] Slower gastric emptying changes the absorption rate of oral co-administered substances. Because quercetin is taken orally, delayed gastric transit could alter quercetin's absorption kinetics, though the clinical significance is unclear and has not been studied in a dedicated pharmacokinetic trial.

Quercetin's Enzyme and Transporter Effects

Quercetin is well-documented as an inhibitor of several drug-metabolizing enzymes and transporters in in vitro systems. The picture in living humans is more nuanced.

CYP3A4 and CYP2C9 Inhibition

A systematic review of 31 in vitro and in vivo studies published in Drug Metabolism and Disposition reported that quercetin inhibits CYP3A4 with an IC50 of approximately 10 µM in human liver microsomes. [4] At typical oral doses (500 to 1,000 mg), peak plasma quercetin concentrations in humans reach roughly 0.5 to 1.5 µM, well below the in vitro inhibitory threshold. [5] This disconnect between in vitro potency and in vivo plasma levels is a recurring theme in flavonoid pharmacology and is why many observed in vitro interactions do not translate to clinically meaningful effects in humans.

CYP2C9 inhibition by quercetin is more relevant for drugs like warfarin or certain NSAIDs. Since semaglutide is not a CYP2C9 substrate, this pathway does not affect Wegovy directly.

P-Glycoprotein Effects

P-glycoprotein (P-gp, ABCB1) is an efflux transporter that limits intestinal absorption of many drugs. Quercetin inhibits P-gp in cell-based systems. [6] Again, semaglutide is administered subcutaneously and is not a documented P-gp substrate, reducing the clinical relevance of this finding for Wegovy users specifically.

OATP and Other Uptake Transporters

Some flavonoids inhibit organic anion-transporting polypeptides (OATPs), which affect hepatic uptake of statins and certain other drugs. If a Wegovy patient is also taking rosuvastatin or atorvastatin, the combination of quercetin plus a statin may carry more meaningful interaction risk than quercetin plus semaglutide itself. [7] This is worth raising with a prescriber independently of the semaglutide question.

The More Relevant Concern: Pharmacodynamic Interaction

The interaction that actually warrants monitoring is not enzyme-based. It is additive.

Quercetin and Blood Glucose Lowering

Quercetin independently lowers fasting blood glucose in humans. A meta-analysis of 17 randomized controlled trials (total N = 1,068) published in Phytotherapy Research in 2022 reported that quercetin supplementation at doses of 500 to 1,000 mg/day reduced fasting blood glucose by a mean of 3.9 mg/dL (95% CI 1.4 to 6.4 mg/dL) and HbA1c by 0.18% compared to placebo. [8] The effect was larger in participants with type 2 diabetes at baseline.

Semaglutide 2.4 mg lowers fasting glucose through a different mechanism: GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces hepatic glucose output. In the STEP-1 trial (N = 1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, and significant reductions in fasting glucose were observed across the trial population. [9]

When both agents are present, additive glucose lowering is the expected result. For most Wegovy patients this is not dangerous by itself, because semaglutide's insulin-releasing effect is glucose-dependent and carries very low intrinsic hypoglycemia risk. The risk increases if the patient is also taking a sulfonylurea, insulin, or another agent with glucose-independent insulin release.

Antihistamine Effects and Appetite Regulation

Quercetin has documented mast-cell-stabilizing and histamine-inhibiting activity. [10] Some data suggest that histamine plays a modest role in appetite regulation via hypothalamic H1 receptors. First-generation antihistamines are well-known to cause weight gain, partly through H1 blockade. Whether quercetin's relatively weak antihistamine effect at standard doses could partially blunt GLP-1-driven appetite suppression is speculative. No clinical trial has tested this combination directly. The effect, if present, is likely small compared to semaglutide's dominant appetite-suppressing action.

GI Symptom Overlap

Wegovy commonly causes nausea, diarrhea, and abdominal discomfort, particularly during dose escalation. High-dose quercetin (above 1,000 mg/day) may also produce GI side effects in some users. [2] The overlap makes it harder to attribute symptoms to one agent versus the other. Starting quercetin at a lower dose (250 to 500 mg/day) during Wegovy titration is a practical way to keep the symptom picture interpretable.

What High-Dose Quercetin Studies Show

Most human safety data for quercetin comes from trials using 500 to 1,000 mg/day for 8 to 12 weeks. A 12-week trial in overweight adults (N = 92) published in Free Radical Biology and Medicine found no adverse liver or kidney markers at 1,000 mg/day. [11] A separate Phase I safety study using quercetin at 2,000 mg/day for 3 weeks in healthy adults reported mild, transient headache and nausea in three of 25 participants, but no serious adverse events. [12]

No published human trial has evaluated quercetin specifically in semaglutide-treated patients. The Natural Medicines database currently rates the interaction between quercetin and semaglutide as having insufficient evidence for a formal severity rating, which reflects the absence of dedicated interaction studies rather than confirmed safety.

Original HealthRX Clinical Decision Framework

The HealthRX medical team uses the following four-question framework when evaluating any supplement alongside a GLP-1 receptor agonist. This framework is not a substitute for personalized medical advice.

Question 1. Is the supplement metabolized by a pathway semaglutide depends on? Semaglutide uses proteolytic cleavage and beta-oxidation, not CYP450. For quercetin: No relevant shared pathway.

Question 2. Does the supplement inhibit enzymes or transporters that handle semaglutide? Semaglutide is not a CYP3A4, CYP2C9, or P-gp substrate. For quercetin at standard doses: No clinically meaningful pharmacokinetic interference expected.

Question 3. Does the supplement produce the same pharmacodynamic effects as semaglutide? Both quercetin and semaglutide lower blood glucose. Risk increases when additional glucose-lowering drugs are present. Monitor fasting glucose if combining.

Question 4. Do the adverse-effect profiles overlap in a way that complicates monitoring? Both can cause GI symptoms. Keep quercetin dose at or below 500 mg/day during Wegovy titration to maintain interpretable symptom attribution.

Drug-Specific Context: Semaglutide Prescribing Information Guidance on Supplements

The FDA-approved Wegovy label does not specifically address quercetin. The label does note that semaglutide slows gastric emptying and that this "may influence the absorption of concomitantly administered oral medications." [3] The label instructs prescribers to monitor patients who take oral medications with narrow therapeutic windows when initiating Wegovy.

Quercetin does not have a narrow therapeutic window, so this warning does not directly apply. Still, slowed gastric emptying could alter the time-to-peak absorption of quercetin, potentially changing when quercetin exerts its peak enzymatic inhibitory effects relative to co-administered CYP-sensitive drugs. Patients taking both quercetin and a CYP3A4-sensitive medication (e.g., cyclosporine, tacrolimus) on Wegovy should flag this three-way interaction to their prescriber. [3]

Monitoring Recommendations

For patients already combining quercetin and semaglutide 2.4 mg, the following monitoring approach is reasonable.

Blood Glucose Tracking

Check fasting capillary glucose weekly for the first four weeks after adding quercetin if you have type 2 diabetes or prediabetes. Hypoglycemia is unlikely unless sulfonylureas or insulin are co-prescribed, but an unexplained drop in fasting glucose below 70 mg/dL should prompt a prescriber conversation.

The American Diabetes Association Standards of Care in Diabetes 2024 defines hypoglycemia as a blood glucose <70 mg/dL (Level 1) and <54 mg/dL (Level 2, requiring immediate treatment). [13] Patients should familiarize themselves with these thresholds before adding any supplement with independent glucose-lowering activity.

GI Symptom Diary

Keep a brief daily log during the first four weeks when starting quercetin alongside Wegovy. Record nausea, loose stools, and abdominal pain on a 0-to-3 scale. If symptoms worsen versus your Wegovy baseline, reduce or discontinue quercetin before adjusting the semaglutide dose.

Liver and Kidney Panel

A standard metabolic panel (CMP) at the next routine visit is sufficient for patients at typical quercetin doses (500 to 1,000 mg/day). No evidence currently supports additional liver function testing beyond standard clinical practice for this combination.

Special Populations

Patients with Type 2 Diabetes on Additional Agents

The STEP-2 trial enrolled adults with type 2 diabetes (N = 1,210) and found that semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points versus 0.4 percentage points for placebo at 68 weeks. [14] If quercetin adds another 0.18 percentage points of HbA1c reduction in this population, [8] the combined glucose-lowering effect is meaningful. Patients in this group who are also on sulfonylureas or insulin must discuss the combination with their prescriber before starting quercetin.

Patients Taking Immunosuppressants

Cyclosporine and tacrolimus are CYP3A4 and P-gp substrates with narrow therapeutic windows. The interaction risk in this group is not with semaglutide but with the immunosuppressant. Quercetin should not be added to such a regimen without transplant team approval. [6]

Patients with Estrogen-Sensitive Conditions

Quercetin has weak phytoestrogenic activity in cell-based models. Current human evidence does not support a clinically significant estrogenic effect at standard supplement doses, but patients with hormone-receptor-positive breast cancer or certain gynecologic conditions should discuss quercetin with their oncologist or gynecologist before using it. [15]

Practical Guidance: If You Want to Take Both

1. Choose a standard quercetin product at 500 mg per day, not a high-dose formulation above 1,000 mg.
2. Take quercetin at a consistent time each day. No dose-separation window is required to prevent a pharmacokinetic interaction with semaglutide specifically, but separating it from any other oral CYP3A4-sensitive drug by at least two hours is good general practice.
3. Tell your prescriber and pharmacist you are adding quercetin. A complete medication and supplement list allows your care team to catch interactions with other drugs in your regimen.
4. Do not self-adjust your Wegovy dose based on changes in fasting glucose after starting quercetin.
5. If GI symptoms worsen within the first two weeks, hold quercetin for seven days before reintroducing.

As the FDA Wegovy prescribing information states: "patients should be advised of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion." [3] Adding any supplement that shares GI side effects increases the practical burden of that monitoring.

How Quercetin Compares to Other Common Wegovy Supplements

Many patients ask about several supplements simultaneously. A brief comparison helps contextualize the quercetin risk level.

Berberine is the supplement with the most clinically significant pharmacodynamic overlap with semaglutide because it activates AMPK and lowers glucose through mechanisms that stack more aggressively with GLP-1 action. A 2022 meta-analysis found berberine reduced fasting glucose by 16.5 mg/dL in type 2 diabetes. [16] That is a larger effect than quercetin's 3.9 mg/dL reduction, making berberine a higher-priority conversation with a prescriber.

Fish oil (omega-3 fatty acids) at standard doses (1 to 4 g/day) has no meaningful pharmacokinetic interaction with semaglutide and may complement its cardiovascular risk profile. The SELECT trial (N = 17,604) demonstrated semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with cardiovascular disease and overweight or obesity. [17] Fish oil at prescription doses (icosapent ethyl 4 g/day) also reduces cardiovascular events. The two agents are generally considered compatible.

Magnesium, vitamin D, and zinc at standard doses carry no documented pharmacokinetic interactions with semaglutide and are generally considered compatible.

Quercetin sits in a middle tier: lower concern than berberine, but warranting a brief prescriber conversation and glucose monitoring for patients with diabetes or on glucose-lowering polypharmacy.